Skip to navigation Skip to content

Clinical Trial: Nabiximols Oromucosal Spray as Add-on Therapy in People With Spasticity Due to MS

Share

Details
Type of MS: PPMS|PRMS|RRMS|SPMS
Treatment mode of action: To reduce spasticity
Number of Subjects: 446
Medication: Nabiximols Oromucosal Spray
Location: North Carolina
Institutions: Accellacare
1901 S. Hawthorne Road Suite 306 
Winston-Salem, North Carolina 27103 Contact Information
Tessa Santarpia
336-347-4361
patientmatch@accellacare.com

Funding:

Jazz Pharmaceuticals

Description

Accellacare is now enrolling men or women, age 18+, to participate in a research study in Winston-Salem, North Carolina. Participants must have been diagnosed with multiple sclerosis for at least 12 months. Participants also should be currently receiving optimized treatment with at least 1 oral anti-spasticity medication, and display spasticity symptoms, including muscle spasms.

This study includes a 28-day baseline period, a 12-week treatment period and a 2-week follow up period, throughout which participants will be closely monitored by healthcare providers. The treatment period involves 1 spray/day of the investigational product. Health insurance is not required, as participants receive all study medication and care at no cost, as well as financial reimbursement for time and travel.

Share


© 2022 The National Multiple Sclerosis Society is a tax exempt 501(c)3 nonprofit organization. Its Identification Number (EIN) is 13-5661935.